Matches in Ubergraph for { <http://purl.obolibrary.org/obo/NCIT_C158617> ?p ?o ?g. }
Showing items 1 to 53 of
53
with 100 items per page.
- NCIT_C158617 IAO_0000115 "An orally available, selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Upon oral administration, pirtobrutinib selectively and reversibly binds to BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, thereby inhibiting the growth of malignant B-cells that overexpress BTK. Reversible binding of LOXO-305 may preserve antitumor activity in the presence of certain acquired resistance mutations, including C481 mutated BTK, and limit toxicity associated with inhibition of other non-BTK kinases. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes." @default.
- NCIT_C158617 NCIT_A32 NCIT_C1909 @default.
- NCIT_C158617 NCIT_A7 NCIT_C75017 @default.
- NCIT_C158617 NCIT_NHC0 "C158617" @default.
- NCIT_C158617 NCIT_P106 "Pharmacologic Substance" @default.
- NCIT_C158617 NCIT_P107 "Pirtobrutinib" @default.
- NCIT_C158617 NCIT_P108 "Pirtobrutinib" @default.
- NCIT_C158617 NCIT_P208 "CL950650" @default.
- NCIT_C158617 NCIT_P210 "2101700-15-4" @default.
- NCIT_C158617 NCIT_P302 "relapsed or refractory mantle cell lymphoma (MCL)" @default.
- NCIT_C158617 NCIT_P319 "JNA39I7ZVB" @default.
- NCIT_C158617 NCIT_P322 "CTRP" @default.
- NCIT_C158617 NCIT_P322 "FDA" @default.
- NCIT_C158617 NCIT_P322 "GDC" @default.
- NCIT_C158617 NCIT_P329 "797383" @default.
- NCIT_C158617 NCIT_P330 "797383" @default.
- NCIT_C158617 NCIT_P375 "BTK Inhibitor LOXO-305" @default.
- NCIT_C158617 NCIT_P399 "797383" @default.
- NCIT_C158617 normalizedInformationContent "95.413332725061409" @default.
- NCIT_C158617 referenceCount "2" @default.
- NCIT_C158617 hasExactSynonym "5-Amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-((2S)-1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide" @default.
- NCIT_C158617 hasExactSynonym "BTK Inhibitor LOXO-305" @default.
- NCIT_C158617 hasExactSynonym "Jaypirca" @default.
- NCIT_C158617 hasExactSynonym "LOXO 305" @default.
- NCIT_C158617 hasExactSynonym "LOXO-305" @default.
- NCIT_C158617 hasExactSynonym "LOXO305" @default.
- NCIT_C158617 hasExactSynonym "LY3527727" @default.
- NCIT_C158617 hasExactSynonym "PIRTOBRUTINIB" @default.
- NCIT_C158617 hasExactSynonym "Pirtobrutinib" @default.
- NCIT_C158617 inSubset NCIT_C116977 @default.
- NCIT_C158617 inSubset NCIT_C116978 @default.
- NCIT_C158617 inSubset NCIT_C128784 @default.
- NCIT_C158617 inSubset NCIT_C157711 @default.
- NCIT_C158617 inSubset NCIT_C157712 @default.
- NCIT_C158617 inSubset NCIT_C176424 @default.
- NCIT_C158617 inSubset NCIT_C177537 @default.
- NCIT_C158617 inSubset NCIT_C63923 @default.
- NCIT_C158617 type Class @default.
- NCIT_C158617 isDefinedBy ncit.owl @default.
- NCIT_C158617 label "Pirtobrutinib" @default.
- NCIT_C158617 subClassOf NCIT_C124801 @default.
- NCIT_C158617 subClassOf NCIT_C129824 @default.
- NCIT_C158617 subClassOf NCIT_C129825 @default.
- NCIT_C158617 subClassOf NCIT_C1404 @default.
- NCIT_C158617 subClassOf NCIT_C158617 @default.
- NCIT_C158617 subClassOf NCIT_C163758 @default.
- NCIT_C158617 subClassOf NCIT_C163774 @default.
- NCIT_C158617 subClassOf NCIT_C1908 @default.
- NCIT_C158617 subClassOf NCIT_C1909 @default.
- NCIT_C158617 subClassOf NCIT_C1967 @default.
- NCIT_C158617 subClassOf NCIT_C2189 @default.
- NCIT_C158617 subClassOf NCIT_C274 @default.
- NCIT_C158617 subClassOf NCIT_C471 @default.